12:00 AM
 | 
Jun 11, 2007
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Analyst picks & changes
Company Bank Analyst Coverage Opinion Wk chg 6/8 cls
BioMS (TSX:MS) Rodman Elemer Piros Price target Market outperform -4% C$2.55
Piros lowered his target to C$6 from C$7 following a recent C$44.3M ($41.7M) offering. He thinks the company could burn C$52.5M ($49.4M) over the next 12 months.
Celgene (CELG) Baird Christopher Raymond Price target Neutral -5% $58.47
JMP Securities Charles Duncan Price target Market outperform
Raymond raised his target to $60 from $57 and increased his FY08 EPS estimate to $1.62 from $1.55 after CELG presented additional data from the Phase III E4A03 trial of Revlimid plus dexamethasone to treat newly diagnosed multiple myeloma (MM). He expects the data to increase front-line use of the thalidomide analog (see B16).
Duncan raised his target to $75 from $64. He said...

Read the full 840 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >